Breadcrumb navigation

Featured publication

B Malone, C Tosch, B Grellier, K Onoue, T Sztyler, K Rittner, Y Yamashita, E Quemeneur, and K Bendjama, "Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine." AACR. Cancer Research. 2020; 80(16 Suppl): 4566.

The development of therapeutic cancer vaccines to immunize against tumor antigens constitutes a promising modality. Mutation-associated antigens are considered major targets given their specificity to tumor cells. These mutations are specific to the patients and require tailor-made vaccines targeting the corresponding tumor-specific epitopes. Many mutations are identified in the tumoral genome in...Learn more

publication_thumbnail

Publication / Presentation

Jul 23, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 57th Annual Meeting of Liver Cancer Study Group of JapanNEW
Jun 19, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 13th Annual Meeting of Japanese Society of Immunotherapy for Hematological DisordersNEW
May 23, 2021
Y Yamashita, K Bendjama, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 18th Annual Meeting of Japan Research Association for Immunotherapeutics
Apr 16, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; Bring Innovation in the Pharmaceutical Industry
Mar 5, 2021
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 4th Social Smart Dental Hospital Symposium
Nov 29, 2019
Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2019; The 32nd Annual Meeting of the Japan Society for Biological Therapy
Aug 23, 2019

K Onoue, Y Yamashita, B Malone, Y Tanaka, B Grellier, K Bendjama, K Machida, and K Udaka, "Evaluation of HLA-peptide binding prediction method." 2019; The 23rd Annual Meeting of Japanese Association of Cancer Immunology

Research Paper

NEC Labs Europe
Digital Health is a rapidly growing business for the NEC Group. In the Biomedical AI group, we consider challenges from prevention, diagnosis, and through treatment.

Read publication
CYTLIMIC
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine.

Read publication

NEC Labs America
Machine learning is the key technology for data analytics and artificial intelligence. We have been at the forefront of developments in such areas as deep learning, support vector machines and so on for over a decade.

Read publication